We're Keeping An Eye On Aadi Bioscience's (NASDAQ:AADI) Cash Burn Rate

In This Article:

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So should Aadi Bioscience (NASDAQ:AADI) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. Let's start with an examination of the business' cash, relative to its cash burn.

View our latest analysis for Aadi Bioscience

When Might Aadi Bioscience Run Out Of Money?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When Aadi Bioscience last reported its March 2024 balance sheet in May 2024, it had zero debt and cash worth US$88m. Importantly, its cash burn was US$61m over the trailing twelve months. Therefore, from March 2024 it had roughly 17 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
NasdaqCM:AADI Debt to Equity History July 31st 2024

How Well Is Aadi Bioscience Growing?

Some investors might find it troubling that Aadi Bioscience is actually increasing its cash burn, which is up 15% in the last year. The silver lining is that revenue was up 27%, showing the business is growing at the top line. On balance, we'd say the company is improving over time. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Aadi Bioscience To Raise More Cash For Growth?

While Aadi Bioscience seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).